PTC Therapeutics Inc. diskutieren

chancenreich

die ist nicht so schlecht wie der Absturz vermuten lässt

PTC Therapeutics (NASDAQ: PTCT) recently received a number of ratings updates from brokerages and research firms:

• 3/1/2016 – PTC Therapeutics had its price target raised by analysts at Barclays from $40.00 to $100.00. They now have an “overweight” rating on the stock.
• 3/1/2016 – PTC Therapeutics had its “outperform” rating reaffirmed by analysts at Credit Suisse. They now have a $12.00 price target on the stock, down previously from $36.00. etc etc
  

Bullish Lager, die mich in den Top 3 für den Wettbewerb Affe gesetzt wird

PTCT auch deutlich zurückgegangen, kurz nach SRPT die FDA verweigert Translarna Datei aber einige Leben vor kurzem UK NICE gezeigt hat , das Medikament empfohlen

TC Therapeutics with NDA on 28.09.2017

PTC Therapeutics Inc.’s (PTCT) New Drug Application for Translarna, a treatment for nonsense mutation Duchenne muscular dystrophy, is all set to be reviewed by an FDA panel on September 28, 2017.

The FDA’s final decision on Translarna will be known by October 24, 2017.

Translarna is approved within the European Union (EU) Member States, Iceland, Liechtenstein, Norway, Israel and South Korea.

Ever since its launch in December 2014, Translarna has had substantial year-over-year net sales growth.

Sales of Translarna, which were $34 million in 2015, more than doubled to $81 million in 2016. Looking ahead to full-year 2017, the Company expects Translarna to bring home sales in the range of $115 million to $130 million.

The first FDA-approved treatment for DMD is Exondys 51, manufactured by Sarepta Therapeutics Inc. (SRPT). Exondys 51, specifically indicated for patients who have a confirmed mutation of the dystrophin gene amenable to exon 51 skipping, was approved in the U.S. last September.

The second approved drug for DMD is Emflaza, developed by privately held Marathon Pharmaceuticals. Emflaza is also the first drug in the United States approved for use by patients who are 5 years or older with DMD, regardless of genetic mutation.

TC Therapeutics purchased all rights to Emflaza in April of this year.

a +

Bio-Therapeutika

a +